ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE